SCHEMBL12401232

SCHEMBL12401232

CC(C)(C)C(=O)C(NC(=O)CCc1cccnc1)C(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 1/20 0.48
NAMPT P43490 2/20 0.47
TNKS2 Q9H2K2 1/20 0.44
TBXAS1 P24557 8/20 0.44
POLB P06746 1/20 0.43
PSMB8 P28062 1/20 0.43
P2RX7 Q99572 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15219639 0.89 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL12401076 0.87 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9ALDH1A1PSMB8
SCHEMBL12401390 0.87 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9ALDH1A1PSMB8
SCHEMBL12467390 0.86 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL12401273 0.80 SMN1; SMN2 (0.54) ALDH1A1POLBMAPT
SCHEMBL21890782 0.80 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL12331442 0.79 CYP3A4 (0.53) CYP3A4ALDH1A1NAMPTMAPT
SCHEMBL12401235 0.78 UTS2R (0.45) ALDH1A1POLBP2RX7
SCHEMBL8059154 0.78 CYP3A4 (0.62) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL12376674 0.77 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575208-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 CYP1A2 1349/4885CYP3A4 219/4885CYP2C9 1139/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 CYP1A2 1349/4885CYP3A4 219/4885CYP2C9 1139/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 CYP1A2 1658/4885CYP3A4 527/4885CYP2C9 2460/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CYP1A2 1092/4885CYP3A4 158/4885CYP2C9 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.